APA (7th ed.) Citation

Tan, C. R., Derkach, A., Nemirovsky, D., Ciardiello, A., Diamond, B., Hultcrantz, M., . . . Korde, N. (2023). Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood cancer journal (New York), 13(1), 112-8. https://doi.org/10.1038/s41408-023-00882-y

Chicago Style (17th ed.) Citation

Tan, Carlyn Rose, et al. "Bortezomib, Lenalidomide and Dexamethasone (VRd) Vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal (New York) 13, no. 1 (2023): 112-8. https://doi.org/10.1038/s41408-023-00882-y.

MLA (9th ed.) Citation

Tan, Carlyn Rose, et al. "Bortezomib, Lenalidomide and Dexamethasone (VRd) Vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal (New York), vol. 13, no. 1, 2023, pp. 112-8, https://doi.org/10.1038/s41408-023-00882-y.